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Abstract
Context—Recent studies have shown an association between cigarettes per day (CPD) and a
nonsynonymous single-nucleotide polymorphism in CHRNA5, rs16969968.
Objective—To determine whether the association between rs16969968 and smoking is modified
by age at onset of regular smoking.
Data Sources—Primary data.
Study Selection—Available genetic studies containing measures of CPD and the genotype of
rs16969968 or its proxy.
Data Extraction—Uniform statistical analysis scripts were run locally. Starting with 94 050
ever-smokers from 43 studies, we extracted the heavy smokers (CPD >20) and light smokers
(CPD ≤10) with age-at-onset information, reducing the sample size to 33 348. Each study was
stratified into early-onset smokers (age at onset ≤16 years) and late-onset smokers (age at onset
>16 years), and a logistic regression of heavy vs light smoking with the rs16969968 genotype was
computed for each stratum. Meta-analysis was performed within each age-at-onset stratum.
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Data Synthesis—Individuals with 1 risk allele at rs16969968 who were early-onset smokers
were significantly more likely to be heavy smokers in adulthood (odds ratio [OR]=1.45; 95% CI,
1.36–1.55; n=13 843) than were carriers of the risk allele who were late-onset smokers (OR =
1.27; 95% CI, 1.21–1.33, n = 19 505) (P = .01).
Conclusion—These results highlight an increased genetic vulnerability to smoking in early-
onset smokers.
Tobacco use is the leading cause of preventable death worldwide, killing more than 5
million people annually.1,2 Smoking behaviors, including nicotine dependence, cluster in
families,3 and large twin studies,4–9 indicate that this clustering reflects genetic factors.
Completion of the Human Genome Project, coupled with rapid advances in genotyping
technology, has led to association studies that harness natural genetic variation to gain
insight into the genetic basis for smoking behaviors.
Numerous studies10–19 have demonstrated an association between the nonsynonymous
chromosome 15 single-nucleotide polymorphism (SNP) rs16969968, in the α5 nicotinic
receptor subunit gene CHRNA5 (often tagged by rs1051730), and smoking behavior, as
measured by cigarettes per day (CPD) and nicotine dependence. This association is
consistent with biological evidence suggesting the risk variant alters conductance of the α5-
containing nicotinic receptors.20,21 Of note, the same locus is associated with risk of lung
cancer and chronic obstructive pulmonary disease in several genome-wide association
studies.14,18,22,23
Because rs16969968 has a significant genetic effect on smoking behavior, it is important to
understand how this genetic variant interacts with various factors, including potentially
modifiable risk factors. In particular, age at onset of regular smoking is of interest because
of the well-established association between early age at onset of smoking and higher risk of
heavier smoking and nicotine dependence.9,24–26
An unresolved issue is whether rs16969968 plays a role in the heightened susceptibility to
nicotine dependence in early-onset smokers.10,27,28 One study10 reported an increased risk
of nicotine dependence at this locus in individuals who started smoking regularly at or
before age 16 years. In contrast, a second study27 found a stronger association with this
locus in smokers with age at onset of 16 years or older compared with smokers with an
earlier age at onset. The task of interpreting and reconciling published results is further
complicated because the definition of nicotine dependence and age at onset of smoking
varied across studies.
Multiple investigators collaborated on this meta-analysis of the effect of the interaction
between age at onset and rs16969968 on the risk of heavy smoking, contributing 43
individual data sets for a total of 94 050 past or current smokers. In addition to age at onset
and rs16969968, we evaluated sex, birth cohort, and educational attainment in these
analyses, variables that are related to smoking and easily harmonized across studies. To our
knowledge, this study is the first large-scale systematic investigation of variation in the
association between rs16969968 and CPD across strata of age at onset of smoking and other
individual characteristics, a significant step in deepening our understanding of how we can
modify genetic associations for smoking behaviors.
METHODS
STUDY PARTICIPANTS
This study is a meta-analysis of 94 050 individuals from 43 data sets. Written informed
consent was obtained from all the participants. Inclusion in the study required (1) reported
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number of CPD and (2) the availability of genotype data for rs16969968 or its proxy
(rs1051730). All the participants were ever-smokers of European descent aged 25 years or
older; within each sample, only unrelated individuals were included. The sample sizes for
each of the studies included in this meta-analysis are listed in the Table. A brief description
of each sample is provided in eAppendix 1 (http://www.archgenpsychiatry.com).
ETHICS STATEMENT
This study was conducted according to the principles expressed in the Declaration of
Helsinki and obtained informed consent from participants and approval from the appropriate
institutional review boards.
VARIABLES
The primary variables examined were smoking quantity (CPD) and age at onset of regular
smoking. Secondary variables were sex, birth cohort, and educational attainment. The text
used to ascertain these variables for each study is given in eTable 1.
Previously published meta-analyses of smoking behavior have used 2 different codings of
CPD: (1) heavy smoking (CPD >20) vs light smoking (CPD ≤10), excluding the
intermediate group,19 and (2) CPD as a linear variable coded 0 (CPD ≤10), 1 (CPD of 11–
20), 2 (CPD of 21–30), and 3 (CPD >30).16–18 We used both variables for these meta-
analyses. The 2 variables gave similar beta values and statistically similar results. For ease
of interpretation, results are reported for heavy vs light smoking. The results using CPD as a
linear variable are given in eTable 2.
Age at onset of regular smoking was dichotomized as 16 years and younger or older than 16
years, representing the median of smoking onset for smokers of all ages surveyed between
1992 and 2002 in the United States (http://riskfactor.cancer.gov/studies/tuscps/info.html).
This definition corresponds to the dichotomization of age at onset of smoking used by Weiss
and colleagues.10 Of the 94 050 current or former smokers in the samples, 61 128 had age at
onset of smoking reported, and 33 348 of these were either heavy smokers (CPD >20) or
light smokers (CPD ≤10). There were current and former smokers in both groups. These 33
348 individuals, analyzed separately at each site, represent the individuals included in the
primary meta-analysis.
The SNP of interest is rs16969968. However, the most frequently genotyped tag SNP for
rs16969968 is rs1051730, which has an r2= 1.00 with rs16969968 based on the CEU 1000
Genomes sample.29,30 Therefore, rs1051730 was used in analyses when rs16969968 was
unavailable. We report the results as an association with rs16969968 because (1) they are
statistically equivalent results and (2) there is biological evidence that rs16969968 alters
receptor function.21 The minor allele frequency for each sample in the meta-analysis is
given in the Table.
QUALITY CONTROL
Genotyping of each data set was performed locally. Strict quality control measures were
implemented at each site and are detailed in eAppendix 1. For the meta-analysis, we
implemented quality control procedures to ensure that data from individual studies were
analyzed correctly. Specifically, we examined univariate and multivariate distributions of all
the variables in each study to ensure consistent coding within and across studies.
STATISTICAL ANALYSES
To ensure uniform analyses, scripts in a commercially available software program (SAS;
SAS Institute, Inc) and in the freeware program R (http://www.r-project.org) for genetic
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association analyses were developed centrally and were distributed following protocols
similar to those of Saccone et al.19 The scripts were executed by each participating group,
and the results were returned to the coordinating group, where the meta-analysis was
performed.
The diversity of individual data sets did not allow for a single reference group for age at
onset of smoking across all studies. Accordingly, each site performed logistic regressions
with heavy vs light smoking as the dependent variable (modeling the probability of heavy
smoking) and sex and rs16969968 (coded additively) as the independent variables, stratified
by age at onset of smoking (in individuals with age at onset of smoking ≤16 years and >16
years). Heterogeneity in the meta-analysis was assessed using the goodness-of-fit statistic Q
′, detailed in eAppendix 2.
To evaluate the robustness of these findings, we explored the sensitivity of the results to
alternative codings of CPD and age at onset. The 2 alternative CPD codings used included
(1) heavy smoking (CPD >20) vs light smoking (CPD ≤10), excluding the intermediate
group, and (2) CPD as an ordinal variable coded 0 (CPD ≤10), 1 (CPD of 11–20), 2 (CPD of
21–30), and 3 (CPD >30), as described previously herein. The 3 alternative codings of age at
onset included (1) dichotomized as 16 years or younger or older than 16 years (primary
variable); (2) categorized as younger than 15, 15 to 16, 17 to 18, and older than 18 years;
and (3) categorized by within-study quartile. The results of the secondary analyses are
presented in detail in eAppendix 3.
The interaction between the secondary variables (sex, birth cohort, and educational
attainment) and rs16969968 on smoking behavior was evaluated by a stratified meta-
analysis of CPD (coded as a 4-level trait). These results are presented in eFigures 1 to 4.
RESULTS
Figure 1 shows the meta-analysis forest plots for the association between heavy vs light
smoking and the rs16969968 A allele, stratified by early- and late-onset smoking.
Specifically, this meta-analysis tests whether the genetic risk for heavy smoking, based on
the rs16969968 A allele, is different between early- and late-onset smokers (n=33 348).
Smokers in the intermediate smoking level were excluded (CPD of 11–20). Compared with
individuals with the rs16969968 GG genotype (wild-type allele), the odds ratio (OR) in
early-onset smokers was 1.45 (95% CI, 1.36–1.55) for individuals with AG genotypes and
2.10 (95% CI, 1.97–2.25) for individuals with AA genotypes. In late-onset smokers, the OR
is 1.27 (95% CI, 1.21–1.33) for individuals with AG genotypes and 1.61 (95% CI, 1.54–
1.69) for individuals with GG genotypes. The difference between the OR in early-onset
smokers and the OR in late-onset smokers is significant (P =.01). However, the current
model does not adequately capture the heterogeneity among data sets: the heterogeneity χ2
value (Q′) was calculated to be 117 (P<.001, 69 df).
The relationship among smoking, genotype, and age at onset of smoking is detailed in
Figure 2. Consistent with previous work, early onset of smoking and rs16969968 contribute
to the risk of heavy smoking. Initiating smoking earlier than 16 years of age is significantly
associated with higher risk of heavy smoking (OR = 2.63, unadjusted for genotype; 95% CI,
2.49–2.78; P < .001). The A allele at rs16969968 is associated with a higher risk of heavy
smoking (OR=1.28 per A allele, unadjusted for age at onset; 95% CI, 1.25–1.32; P < .001,
modeled additively). The interaction between early-onset smoking and the A allele at
rs16969968 is 1.16 (P =.01), with OR=1.27 in late-onset smokers compared with OR = 1.46
in early-onset smokers. In Figure 2, the interaction is illustrated by the larger differences
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between bar heights in the early-onset data compared with the late-onset data, corresponding
to a larger genetic effect in the early-onset group.
Because early-onset smoking is a strong risk factor for heavy smoking in adulthood and age
at onset of smoking is a heritable characteristic, we must consider the possibility that a
shared genetic factor could lead to early-onset smoking and heavy smoking in adulthood.
However, rs16969968 does not seem to be a shared genetic factor between early-onset
smoking and heavy smoking. Specifically, no association was seen between dichotomized
age at onset and rs16969968 in this sample of 67 128 smokers (P = .77). This suggests that a
direct relationship between rs16969968 and age at onset is unlikely to explain the observed
association between smoking quantity and rs16969968 in early-onset smokers.
The robustness of the statistical interaction was evaluated by varying the way in which CPD
and age at onset were modeled. Finding an increased genetic association in early-onset
smokers seems robust across CPD phenotypes and definitions of early onset. There was no
statistical interaction observed between rs16969968 and sex, birth cohort, or educational
attainment. The results of these analyses are detailed in eFigures 1 to 4 and eTables 1 and 2.
COMMENT
Once genetic factors contributing to disease susceptibility have been identified, the next goal
is to find factors that can reduce an individual’s genetic risk. We designed this large meta-
analysis to determine whether age at onset modifies a known genetic association with
smoking behavior. We found that the genetic risk of heavy smoking (as measured by the
rs16969968 A allele) is greater in early-onset smokers (onset of smoking at ≤16 years)
compared with later-onset smokers. These results are consistent with the findings of Weiss
and colleagues10,28 and are supported by animal models in which the developing adolescent
brain has been shown to be particularly vulnerable to addictive effects of nicotine31–35 and
by human studies suggesting that adolescent neurodevelopment is a particularly vulnerable
period for the development of addiction.36 In addition, the increased association in early-
onset smokers is consistent with the epidemiologic observation of increased vulnerability to
dependence in early-onset smokers.9,24,26 With this large international collaborative
analysis, we also demonstrated that the stronger association of rs16969968 in white early-
onset smokers is consistent across different continents (North America, Europe, and
Australia).
The finding of a stronger genetic risk in early-onset smokers supports public health
interventions to reduce adolescent smoking. However, of the variables evaluated in this
study, the strongest single risk factor of heavy smoking is early-onset smoking, highlighting
the importance of a reduction in adolescent smoking across the entire population, not just in
individuals with the risk allele of rs16969968. Nonetheless, there is a robust debate on
whether policy and other interventions aimed at curbing early use would have significant
effects on the development of dependence and related health problems over the long term.
Although early use is associated with greater vulnerability to addiction,9,24 early use is also
associated with a variety of behaviors reflecting a vulnerability already in place before the
onset of use.37 Accordingly, early use may not cause greater vulnerability to addiction;
instead, early use and vulnerability to addiction may have a shared etiology.
Age at onset of regular smoking is a heritable trait consistently documented by twin studies,
and it is influenced by environmental exposures, such as parental smoking and peer
smoking.37 In addition, there is evidence from twin studies for a shared susceptibility to
early-onset smoking and nicotine dependence.37 Therefore, it is interesting that we did not
observe a direct association between rs16969968 and age at onset. Further analyses suggest
that this result is robust to adjustment for sex, age, and coding of age at onset. We cannot
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rule out the possibility that unmeasured variables suppressed a true association between
rs16969968 and age at onset. Further study is warranted to investigate the relationship
between early smoking behaviors and genes in this region to improve our understanding of
the mechanism by which age at onset modifies the genetic association with heavy smoking.
It is somewhat sobering to note that despite (1) the strong effect of age at onset on smoking
behavior, (2) the strong genetic effect of the rs16969968 genotype on smoking behavior, and
(3) the subjectively meaningful interaction between the 2 effects (increasing the OR per
genotype from 1.27 to 1.46), the large sample detected this interaction with a somewhat
modest P=.01. This result highlights the power needed to detect gene-environment
interactions in complex disease.
There are several limitations of this study. First, as in any meta-analysis, this study is based
on heterogeneous samples with differential assessment of measures. In addition there was
statistical evidence of heterogeneity. Heterogeneity likely contributes to a lack of precision
in this analysis. However, because misclassification is independent of genotype, any bias
under the alternative hypothesis would decrease the power of the study (leading to an
underestimate of the interaction effect).38 Since we had adequate power to detect an
interaction on heavy vs light smoking between rs16969968 and age at onset of regular
smoking, improved homogeneity of the studies should only strengthen this result.
Although rs16969968 is the most strongly associated SNP genome-wide, multiple
associations in the region form haplotypes associated with varying risk of smoking
behavior.10,16–19 Furthermore, although this article references rs16969968 as the likely
causal association, more than half of the studies used the SNP rs1051730 to tag rs16969968,
and there are multiple other SNPs spanning the CHRNA5-CHRNA3-CHRNB4 cluster that
are indistinguishable from rs16969968 in populations of European descent. Therefore, the
SNP analysis is a simplification of the true genetic model and does not represent the full
complexity of the relationship of age at onset with the association between genotype and
smoking in this region. In addition, further study is required to better understand other
modifiers of the association between CPD and rs16969968. For example, parental
monitoring and peer smoking have been shown to modify this genetic association.39,40
A potential source of bias in the data is early death due to smoking in early-onset smokers.
This could artificially cause an interaction between rs16969968 and early smoking onset if
the early deaths were preferentially in individuals who lack the risk allele. However, if this
were the case, we would expect to see a stronger interaction among individuals born in the
1920–1939 birth cohort compared with in the 1960–1979 birth cohort, which is not the case.
In summary, in a large meta-analysis, we found an increased association between CPD and
rs16969968 in early-onset smokers, which helps explain the epidemiologic observation of
increased rates of nicotine dependence in early-onset smokers. These results provide further
compelling evidence in support of public health interventions targeting adolescent smoking.
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Figure 1.
Odds ratios (ORs) for heavy vs light smoking and rs16969968 A allele across studies where
individuals are stratified by age at onset of regular smoking (AOS) of 16 years or younger vs
older than 16 years. The P value for the difference between early onset and late onset is P= .
01, based on 33 348 heavy and light smokers. The studies are grouped by continent to allow
for cross-cultural comparisons. NA indicates not available.
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Figure 2.
Meta-analysis of the association between the rs16969968 genotype and heavy (cigarettes per
day [CPD] >20) vs light (CPD ≤10) smoking, stratified by early-onset (age at onset ≤16
years) and late-onset (onset >16 years) smoking. Odds ratios (ORs) are given relative to late-
onset smokers with the GG genotype. Effect of the interaction between the rs16969968 A
allele and early-onset smoking on risk of heavy smoking: OR = 1.16, n = 36 936, P= .01.
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Table 1
Table Sample Sizes and A Allele Frequencies of rs16969968 for Studies Included in This Meta-analysis
Study Participants, No. (n = 94 050) Allele Frequency of rs16969968-A
US Data Set
AddHealth 469 0.31
ACS-COPD 2775 0.35
ACS-LCA 1005 0.38
ARIC 9713 0.34
COGA 1704 0.34
COGEND 2073 0.35
Dental cariesa 639 0.36
EAGLE-PLCOa 5955 0.40
GEOS 477 0.37
KCI-WSU 979 0.38
LHS 1943 0.39
LHS-Utah 1943 0.39
MDACC-LCAa 2291 0.37
MDACC-Melanomaa 847 0.33
MGS 2988 0.34
NHS-BRCAa 1198 0.35
NHS-CHDa 724 0.35
NHS-T2Da 1590 0.34
NYS-FS 751 0.34
SMOFAMa 146 0.34
UTAHa 484 0.39
VA-Twin 2768 0.33
Yale 1300 0.35
Australian Data Set
NAG AUSa 1329 0.36
European Data Set
BOMA 1050 0.36
deCODEa 16 404 0.35
DNBCa 370 0.34
FINRISK 7864 0.33
GenMetSa 648 0.34
HGF 719 0.42
KORA 1319 0.34
KORCULAa 384 0.39
LOLIPOP 646 0.31
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Study Participants, No. (n = 94 050) Allele Frequency of rs16969968-A
US Data Set
MUC12 casesa 421 0.36
MUC12 controlsa 235 0.34
MUCMD casesa 641 0.37
MUCMD controlsa 1052 0.35
NAG-Fina 733 0.37
NESDA 1248 0.29
NFBC1966a 3067 0.32
NTR1a 1777 0.39
NTR2a 1173 0.31
SardiNIA 531 0.35
SHIP 4081 0.34
VISa 436 0.39
WTCCC-CAD 1221 0.32
WTCCC-HT 801 0.30
YFSa 694 0.32
aUsed rs1051730 instead of rs16969968 (r2 = 1.00, based on CEU 1000 Genomes data).
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